$SRRK 90 DAYS STOCK PRICE FORECAST

Stock Price

About the Company

Scholar Rock is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. Scholar Rock is creating a pipeline of novel product candidates with the potential to transform the lives of patients suffering from a wide range of serious diseases, including neuromuscular disorders, cancer, fibrosis and anemia. Scholar Rock's approach to targeting the molecular mechanisms of growth factor activation enabled it to develop a proprietary platform for the discovery and development of monoclonal antibodies that locally and selectively target these signaling proteins at the cellular level. By developing product candidates that act in the disease microenvironment, the Company intends to avoid the historical challenges associated with inhibiting growth factors for therapeutic effect. Scholar Rock believes its focus on biologically validated growth factors may facilitate a more efficient development path.

CEO

Nagesh Mahanthappa

Exchange

NASDAQ

Website

www.scholarrock.com

$18M

Total Revenue

119

Employees

$927M

Market Capitalization

-7.55

Price/Earning ratio

Similar Companies

Name Ticker Market Capitalization (USD M) Revenue (USD M) Price/Book Price/Earning Net Margin (%)
Charles River Laboratories Int CRL 21297 3273 9.08 53.74 12.10
Exact Sciences Corp. EXAS 13407 1760 4.00 -15.77 -46.50
PRA Health Sciences Inc PRAH 10739 3333 6.88 50.52 6.40
Syneos Health Inc SYNH 10131 4980 3.01 40.54 5.04
Medpace Holdings Inc MEDP 8027 1094 8.45 43.73 16.65
Vir Biotechnology Inc VIR 6064 284 6.86 -55.35 -35.98
Exelixis Inc EXEL 5290 1254 2.47 32.31 13.10
Twist Bioscience Corp TWST 4280 127 7.36 -32.52 -106.59
Allakos Inc ALLK 3929 7.67 -17.95 None
Recursion Pharmaceuticals Inc RXRX 3213 10 5.37 -21.85 None
Sana Biotechnology Inc SANA 3212 3.99 -8.95 None
Instil Bio Inc TIL 2808 0 4.67 -23.66 None
Allogene Therapeutics Inc ALLO 2539 38 2.80 -10.15 -652.24
Lyell Immunopharma Inc LYEL 2282 10 2.32 -11.06 None
Erasca Inc ERAS 1806 3.81 -11.16 None
Verve Therapeutics Inc VERV 1581 4.12 -14.08 None
Constellation Pharmaceuticals CNST 1564 4.32 -11.18 None
Pandion Therapeutics Inc PAND 1501 1069 1.83 -13.34 -10.55
Sorrento Therapeutics Inc SRNE 1485 51 12.12 -4.24 -692.36
Replimune Group Inc REPL 1419 2.85 -14.34 None
Organogenesis Holdings Inc ORGO 1279 446 6.54 19.63 13.94
Alx Oncology Holdings Inc ALXO 1240 1 3.26 -21.24 -401.23
AlloVir Inc ALVR 1104 0 4.34 -12.03 -718.59
National Research Corp NRC 1097 144 12.91 30.14 24.95
Caribou Biosciences Inc CRBU 1081 8 2.68 -17.15 -787.07
Rubius Therapeutics Inc RUBY 1066 4.98 -5.84 None
Castle Biosciences Inc CSTL 1006 86 2.58 -33.81 -34.46
Scholar Rock Holding Corp SRRK 927 18 4.83 -7.55 -672.72
Crinetics Pharmaceuticals Inc CRNX 909 0 6.37 -9.31 -447.78
Nuvalent Inc NUVL 907 3.03 -23.92 None
Design Therapeutics Inc DSGN 870 0 2.25 -31.00 -245.44
Omega Therapeutics Inc OMGA 851 3.85 -14.90 None
Century Therapeutics Inc IPSC 841 1.98 -10.06 None
RAPT Therapeutics Inc RAPT 837 4 4.72 -13.20 7.14
Icosavax Inc ICVX 823 7 2.82 -15.51 -723.56
Tenaya Therapeutics Inc TNYA 814 2.70 -14.38 None
Monte Rosa Therapeutics Inc GLUE 788 2.16 -11.34 None
Tyra Biosciences Inc TYRA 783 2.54 -38.96 None
Precigen Inc PGEN 770 99 6.33 -7.00 -109.91
MeiraGTx Holdings plc MGTX 759 20 4.18 -9.65 -391.81
Kezar Life Sciences Inc KZR 755 6.09 -14.80 None
Sutro Biopharma Inc STRO 731 60 2.65 -4.83 -213.36
Cullinan Oncology Inc CGEM 714 19 1.60 -11.51 -324.14
Y-Mabs Therapeutics Inc YMAB 710 46 3.50 -18.57 -83.20
Ideaya Biosciences Inc IDYA 705 36 2.59 -20.16 -103.19
Imago BioSciences Inc IMGO 701 -9.01 -26.92 None
Janux Therapeutics Inc JANX 633 2 1.71 -30.27 -436.67
Vera Therapeutics Inc VERA 599 7.09 -10.33 None
Talaris Therapeutics Inc TALS 558 2.20 -13.75 None
Immuneering Corp IMRX 530 3 3.34 -18.54 -887.28
Graphite Bio Inc GRPH 514 1.29 -8.53 None
Precision Biosciences Inc DTIL 497 118 5.22 -15.03 -26.91
Vor Biopharma Inc VOR 480 2.08 -6.90 None
Xilio Therapeutics Inc XLO 438 -3.56 -5.73 None
Evelo Biosciences Inc EVLO 420 13.30 -3.44 None
Cortexyme Inc CRTX 417 3.13 -4.73 None
Mirum Pharmaceuticals Inc MIRM 399 16 7.48 -2.25 None
Pyxis Oncology Inc PYXS 389 -5.57 -6.04 None
Werewolf Therapeutics Inc HOWL 370 2.23 -1.95 None
Rallybio Corp RLYB 362 38 1.95 -8.07 -1.07
Cue Biopharma Inc CUE 355 7 5.72 -7.53 -654.54
Sera Prognostics Inc SERA 323 0 2.13 -11.45 None
Acumen Pharmaceuticals Inc ABOS 320 0 1.39 -3.46 -550.91
Aerovate Therapeutics Inc AVTE 313 1.77 -17.41 None
Biomea Fusion Inc BMEA 311 1.63 -10.23 None
MiNK Therapeutics Inc INKT 298 -5.49 -16.64 None
Eliem Therapeutics Inc ELYM 295 1.71 -5.18 None
Cabaletta Bio Inc CABA 289 2.81 -6.96 None
Magenta Therapeutics Inc MGTA 288 1.71 -4.13 None
Oyster Point Pharma Inc OYST 287 18 2.10 -3.54 -450.47
Applied Therapeutics Inc APLT 285 14 3.44 -2.75 -19.41
Candel Therapeutics Inc CADL 279 0 4.37 -5.72 None
Luna Innovations Inc LUNA 271 106 3.32 -821.00 -0.24
Surface Oncology Inc SURF 253 90 1.98 10.05 14.33
Compass Therapeutics Inc CMPX 247 8.47 -3.04 None
Black Diamond Therapeutics Inc BDTX 224 1.03 -1.83 None
Gemini Therapeutics Inc GMTX 211 1088 0.23 1.74 11.24
Sensei Biotherapeutics Inc SNSE 209 1.33 -6.36 None
Impel NeuroPharma Inc. IMPL 204 0 2.70 -3.13 None
Pieris Pharmaceuticals Inc PIRS 199 25 4.35 -3.88 -203.63
INmune Bio Inc INMB 181 0 2.44 -7.68 None
Alzamend Neuro Inc ALZN 177 11.28 -29.00 None
Nextcure Inc NXTC 168 22 0.67 -2.44 -163.57
AquaBounty Technologies Inc AQB 162 1 0.83 -6.76 None
Tscan Therapeutics Inc TCRX 155 8 0.88 -3.62 -522.54
Reneo Pharmaceuticals Inc RPHM 151 0.99 -4.35 None
Elevation Oncology Inc ELEV 147 0.99 -4.73 None
IN8bio Inc INAB 105 2.40 -10.19 None
Unity Biotechnology Inc UBX 104 1 1.89 -1.50 None
Axcella Health Inc AXLA 104 2700 3.00 -1.69 -10.84
HCW Biologics Inc HCWB 101 4 1.85 -14.74 -165.52
BioVie Inc BIVI 98 7.14 -0.79 None
Hookipa Pharma Inc HOOK 97 20 0.75 -1.48 -339.34
Statera BioPharma Inc STAB 86 0 None -2.99 None
Cyclerion Therapeutics Inc CYCN 73 4 1.52 -1.21 None
RenovoRx Inc RNXT 61 3.44 -12.54 None
Synaptogenix Inc SNPX 53 1.67 -3.51 None
NanoViricides Inc NNVC 50 1.85 -5.55 None
Monopar Therapeutics Inc MNPR 48 2.39 -5.69 None
Acurx Pharmaceuticals Inc ACXP 42 3.01 -3.80 None
Eloxx Pharmaceuticals Inc ELOX 42 0 1.91 -0.73 -14.14
Exicure Inc XCUR 41 4 1.12 -0.87 -148.49
Vaccinex Inc VCNX 41 1 3.92 -1.70 -48.71
Scopus Biopharma Inc SCPS 41 234 22.80 -1.65 80.93
TransCode Therapeutics Inc RNAZ 35 1.53 -8.03 None
Rezolute Inc RZLT 35 3.16 -1.46 None
Unicycive Therapeutics Inc UNCY 30 113 1.57 -3.70 7.94
Cyclo Therapeutics Inc CYTH 30 1 5.48 -1.31 -989.80
Cytocom Inc CBLI 30 0 3.88 -12.72 -912.16
CohBar Inc CWBR 29 2.96 -1.69 None
AgeX Therapeutics Inc AGE 25 2 -2.54 -2.75 -502.97
Aridis Pharmaceuticals Inc ARDS 24 1 -7.13 -0.55 -851.00
Kiromic BioPharma Inc KRBP 17 7.37 -1.17 None
Tenax Therapeutics Inc TENX 17 0 4.07 -0.55 -840.64
Geovax Labs Inc GOVX 16 1 1.29 -10.89 -558.09
Xenetic Biosciences Inc XBIO 11 1 0.84 -2.26 -510.87
BioRestorative Therapies Inc BRTX 6 0 -4.01 -0.10 None
Neurotrope Inc NTRP 5 29 0.08 0.76 23.48

Scholar Rock Holding Corp (SRRK)

3d ago, source: Investing.com

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and ...

Notable Scholar Rock Holding Insider Trades $2.8M In Company Stock

17d ago, source: Benzinga.com

Edward H Myles, Insider at Scholar Rock Holding (NASDAQ:SRRK), made a large buy and sell of company shares on November 15, ...

Scholar Rock Holding Corporation (SRRK) Reports Q3 Loss, Tops Revenue Estimates

24d ago, source: Yahoo Finance

Scholar Rock Holding Corporation (SRRK) came out with a quarterly loss of $1.02 per share versus the Zacks Consensus Estimate of a loss of $0.85. This compares to loss of $0.79 per share a year ago.

Scholar Rock Outlines Pivotal Apitegromab Trial Design In Spinal Muscular Atrophy Patients

2d ago, source: Business Insider

Disclaimer | Accessibility Statement | Commerce Policy | Made In NYC | Stock quotes by finanzen.net Scholar Rock Holding Corp (NASDAQ:SRRK) announced the study design for the SAPPHIRE Phase 3 ...

J.P. Morgan Stick to Their Buy Rating for Scholar Rock Holding Corp

13d ago, source: Investing.com

J.P. Morgan analyst Anupam Rama maintained a Buy rating on Scholar Rock Holding (NASDAQ: SRRK) Corp on Friday, setting a price target of $55, which is approximately 86.19% above the present share ...

SRRK

9d ago, source: Seeking Alpha

Combination chart with 2 data series. Chart represents Scholar Rock Holding Corporation price and volume over 1Y period View as data table, Scholar Rock Holding Corporation price and volume The ...

Scholar Rock Announces Design of Phase 3 SAPPHIRE Clinical Trial Evaluating Apitegromab in Non-Ambulatory Patients with Type 2 and Type 3 Spinal Muscu

2d ago, source: 아크로팬

Phase 3 trial is a randomized, double-blind, placebo-controlled trial of apitegromab as add-on to background SMN therapy in non-ambulatory Type 2/3 SMA– Trial design is informed by the positive ...

Scholar Rock Holding Corp SRRK

4d ago, source: Morningstar%2c Inc.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions.

Notable Scholar Rock Holding Insider Trades $2.8M In Company Stock

16d ago, source: Yahoo Finance

Edward H Myles, Insider at Scholar Rock Holding (NASDAQ:SRRK), made a large buy and sell of company shares on November 15, according to a new SEC filing. What Happened: A Form 4 filing from the U ...

Your Portfolio